Small molecule drug could hold promise for treatment of arthritis
A Phase III clinical trial led by Stanford University (CA, USA) has demonstrated that baricitinib may be an effective therapy for refractory rheumatoid arthritis.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>